Brief: Scancell Receives UK MHRA Clinical Trial Authorization For Phase 3 iSCIB1+ In Melanoma
19/08/2026 07:36
BRIEF-Scancell Receives UK MHRA Clinical Trial Authorization For Phase 3 iSCIB1+ In Melanoma Aug 19 (Reuters) - Scancell Holdings PLC SCLP.L:
SCANCELL HOLDINGS - ISCIB1+ MHRA CTA APPROVAL FOR PH3 TRIAL
SCANCELL - RECEIVES UK MHRA CLINICAL TRIAL AUTHORIZATION FOR PHASE 3 ISCIB1+ IN MELANOMA
Source text: ID:nRSS2225Ra
Further company coverage: SCLP.L